Live feed
Filing
SCHEDULE 13G/A
SCHEDULE 13G/A0000947871-25-000779·Avalo Therapeutics, Inc.
Schedule 13G ownership disclosure
Avalo Therapeutics, Inc.
Common Stock, par value $0.001 per share · CUSIP: 05338F306
Event date: 2025-06-30
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- OrbiMed Advisors LLC
Shares: 967,000.00 · Class: 8.9%
- OrbiMed Capital GP IX LLC
Shares: 644,667.00 · Class: 6%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000947871-25-000779
- Form type
- SCHEDULE 13G/A
- Filer
- Avalo Therapeutics, Inc.
- CIK
- CIK 1534120
- Filed
- Aug 14, 2025
- Reporting period
- Jun 30, 2025
- Description
- Schedule 13G beneficial ownership